Hormone therapy of prostatic bone metastases

Area of Science:

• Oncology
• Urology
• Medical Therapeutics

Background:

• Bone metastases from prostate cancer necessitate endocrine therapy for effective management.
• Endocrine therapy is crucial for controlling prostate cancer progression and alleviating symptoms associated with bone metastases.

Purpose of the Study:

• To review the established and emerging endocrine therapies for prostate cancer with bone metastases.
• To discuss the efficacy, side effects, and evolving treatment landscape of prostate cancer endocrine therapy.

Main Methods:

• Review of current endocrine therapy options for prostate cancer bone metastases.
• Analysis of traditional treatments (orchiectomy, estrogens) and newer agents (LHRH analogues, antiandrogens).
• Discussion of combination therapy approaches and the role of prostate-specific antigen (PSA) in monitoring treatment response.

Main Results:

• Endocrine therapy effectively manages prostate cancer in 80-85% of cases, relieving pain and preventing complications.
• Newer agents like LHRH analogues and flutamide offer alternatives to traditional therapies, with potential benefits in combination therapy.
• While LHRH analogues can cause an initial testosterone flare, antiandrogens like flutamide can mitigate this effect.

Conclusions:

• Endocrine therapy remains the cornerstone for treating prostate cancer with bone metastases.
• Novel endocrine therapies, including LHRH analogues and antiandrogens, expand treatment options and are increasingly used, often in combination.
• Prostate-specific antigen (PSA) monitoring simplifies response assessment compared to bone scans.